StockData
Opus Genetics, Inc. logo

Opus Genetics, Inc. (IRD) stock

IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30483% above fair value
$4.06−0.25 (-5.80%)

Close on Nov 12, 2026Market cap $337.78MP/E –Yield –

Opus Genetics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Opus Genetics's profit margin for the twelve months ending Sep 30, 2026 was -1726.7%. For fiscal 2025 it was -349.3%, against -523.4% the year before. The highest annual figure on record is 44.9% in fiscal 2022.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-349.3%+174.1
FY2024Dec 31, 2024-523.4%−471.0
FY2023Dec 31, 2023-52.4%−97.3
FY2022Dec 31, 202244.9%+9670.2
FY2021Dec 31, 2021-9625.3%−9419.7
FY2019Dec 31, 2019-205.6%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-4089.3%−3522.4
Q2 FY2026Jun 30, 2026-1072.6%−815.1
Q1 FY2026Mar 31, 2026-3038.2%−2850.7
Q4 FY2025Dec 31, 2025-427.5%+389.2
Q3 FY2025Sep 30, 2025-566.9%−372.3
Q2 FY2025Jun 30, 2025-257.5%+440.8
Q1 FY2025Mar 31, 2025-187.5%+227.8
Q4 FY2024Dec 31, 2024-816.7%−533.2
Q3 FY2024Sep 30, 2024-194.6%−241.2
Q2 FY2024Jun 30, 2024-698.3%−563.3
Q1 FY2024Mar 31, 2024-415.3%−84.2
Q4 FY2023Dec 31, 2023-283.6%−368.7
Q3 FY2023Sep 30, 202346.6%+911.6
Q2 FY2023Jun 30, 2023-135.0%+7001.0
Q1 FY2023Mar 31, 2023-331.1%−62.6
Q4 FY2022Dec 31, 202285.2%+163.3
Q3 FY2021Sep 30, 2021-865.0%–
Q2 FY2021Jun 30, 2021-7136.0%–
Q1 FY2020Mar 31, 2020-268.5%–
Q1 FY2019Mar 31, 2019-78.1%–

More Opus Genetics figures

See a number that looks wrong?